ReviewCurrent hypertension reviews2025
Nanotechnology-Enhanced Transdermal Patches for Hypertension: A Review.
Review in Current hypertension reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transdermal Drug Delivery System (TDDS) is one of the controlled drug delivery systems whose purpose is to deliver medication through the skin at a predetermined and regulated rate. Nanotechnology has enhanced the skin's absorption of lipophilic, low-molecular-weight medicines with low-dose efficacy, making transdermal drug delivery systems a viable technique for treating various conditions. TDDS permits greater skin permeation of hydrophilic drugs, and scientists are studying macromolecules to improve disease treatment and vaccine development. While additional study is needed to determine nanocarrier safety, this approach could increase the usage of transdermal routes for administering hypertension medicines. As hypertension remains the most prevalent form of cardiovascular illness, we focus on how nanoparticles as skin delivery methods might be used to better treat this global problem. In addition, patients may not be willing to comply with traditional doses due to the greater frequency of drug administration necessary for long-term care of hypertension conditions. Transdermal drug delivery has provided numerous benefits to the medical community since its inception. These benefits include the drug's non-invasive nature, extended therapeutic effect, reduced adverse effects, greater bioavailability, improved patient compliance, and simple termination. This review aims to explore the potential of several antihypertensive drugs for transdermal delivery.
Indexed as
Identifiers
40296629What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.